**

InMed Pharmaceuticals Announces 3.9 Million Share Resale Registration: What it Means for Investors

InMed Pharmaceuticals (NASDAQ: INM), a biotechnology company focused on the development of cannabinoid-based pharmaceuticals, recently announced the registration of 3.9 million shares of its common stock for potential resale. This filing, made with the Securities and Exchange Commission (SEC), has sparked interest and raised questions among investors regarding the company's future trajectory and the potential impact on its stock price. Understanding the nuances of this registration statement is crucial for anyone invested in or considering investing in INM.

Understanding the SEC Filing: What Does it Mean?

The registration statement, filed on Form S-1, doesn't signify that InMed Pharmaceuticals is directly selling these 3.9 million shares. Instead, it allows certain selling stockholders, including existing shareholders, officers, and directors, to sell their shares in the open market over a period of time. This is a common practice, enabling these individuals to liquidate some of their holdings without having to navigate a complex private placement or other alternative sale mechanisms.

Key Takeaways from the Filing:

• No New Shares Issued: Importantly, this registration doesn't involve the issuance of new shares by InMed. This means the company's outstanding share count will remain unchanged. This is a crucial distinction, as a new share offering could dilute existing shareholders' ownership.
• Potential for Share Price Volatility: The potential for a large number of shares to be sold on the open market could create some short-term volatility in the share price. Depending on the selling pressure, the price could decline temporarily. However, it's important to note that the market's reaction to these sales depends on various factors, including overall market sentiment and InMed's ongoing operational performance.
• Transparency and Regulatory Compliance: The filing demonstrates InMed's adherence to SEC regulations and commitment to transparency. By registering these shares, the company ensures that any sales are conducted in a legally compliant manner.

InMed Pharmaceuticals: A Closer Look at the Company

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based pharmaceuticals. The company is actively pursuing several clinical programs, utilizing its proprietary technology platforms to create novel therapeutic solutions. This dedication to research and development is a key factor investors consider when assessing the company's potential.

InMed's Pipeline and Future Prospects:

InMed's pipeline includes several promising drug candidates targeting various therapeutic areas, including:

• Cancer Treatments: InMed is exploring the potential of cannabinoids in the treatment of different forms of cancer.
• Neurological Disorders: Research is underway to investigate the use of cannabinoids in managing neurological conditions.
• Inflammatory Diseases: The company is examining the potential therapeutic benefits of cannabinoids for inflammatory diseases.

The success of these clinical trials will significantly impact InMed's future prospects and its share price. Positive data could lead to increased investor confidence and a rise in the stock price, while negative data could have the opposite effect.

Analyzing the Impact on InMed's Stock Price

The impact of this 3.9 million share resale registration on InMed's stock price is difficult to predict with certainty. While the potential for increased selling pressure exists, several factors could mitigate this impact. These factors include:

• Strong Clinical Trial Results: Positive data from InMed's ongoing clinical trials could counterbalance any downward pressure from share sales.
• Overall Market Conditions: The broader market sentiment will also play a crucial role. A strong market could absorb the increased share supply without significant price declines.
• Investor Sentiment Towards the Company: Positive investor sentiment based on the company's progress and future outlook could offset the impact of the resale.

Investors should carefully consider these factors when evaluating the implications of this SEC filing.

Strategies for Investors:

For investors considering their position in InMed Pharmaceuticals after this announcement, several strategies could be considered:

• Holding: Investors with a long-term outlook and confidence in the company's future may choose to hold their shares.
• Partial Selling: Some investors might choose to partially sell their shares, taking profits while maintaining some exposure to the company's potential.
• Monitoring the Market: Closely monitoring the market's reaction to the share sales and InMed's operational performance is crucial for informed decision-making.

This registration of 3.9 million shares for resale should be viewed within the context of InMed's broader operational landscape and future prospects. The event itself isn't necessarily negative; however, investors should remain informed and consider the potential impact on their portfolio. Conducting thorough due diligence and consulting with a financial advisor is always recommended before making investment decisions.

Keywords: InMed Pharmaceuticals, INM, NASDAQ: INM, SEC filing, Form S-1, share resale, stock price, biotechnology, cannabinoid, pharmaceuticals, clinical trials, investment, investor, stock market, share dilution, selling stockholders, market volatility, cannabis stock, biotech stock, pharmaceutical industry.